Updates are available Correction dated 2025-03-06
Click to view Correction: https://doi.org/10.1186/s13063-025-08783-0
-
Authors
Buccheri, Sergio https://orcid.org/0000-0002-7767-3073
James, Stefan
Mafham, Marion
Landray, Martin
Melvin, Tom
Oldgren, Jonas
Bulbulia, Richard
Bowman, Louise
Hoogervorst, Lotje Anna
Marang-van de Mheen, Perla J.
Juni, Peter
McCulloch, Peter
Fraser, Alan G.
-
Funding
Funding for this research was provided by:
European Union (965246)
Uppsala University
- License Information
-
More Information
Article History
Received: 30 June 2024
Accepted: 10 January 2025
First Online: 21 January 2025
Change Date: 6 March 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13063-025-08783-0
Declarations
:
: Not applicable.
: Not applicable.
: MJL is co-lead of the RECOVERY trial, which is funded by grants from Medical Research Council, National Institute for Health Research, Wellcome, and UK Foreign Development and Commonwealth Office. He designs and conducts randomized clinical trials funded by institution grants from the biopharmaceutical industry (Novartis, Boehringer Ingelheim). He is Chief Executive Officer of Protas, a not-for-profit company established to facilitate the design and conduct of clinical trials and supported through institutional grants and research contracts from NHS England, Google Ventures, Schmidt Futures, Flu Lab, Sanofi, Regeneron, Moderna, Apollo Therapeutics, and BioNTech. He leads the Good Clinical Trials Collaborative, which is funded by Wellcome and Bill & Melinda Gates Foundation. All other authors report no conflicts of interest.
